Men with genetically elevated levels of phenylalanine, a common amino acid found in everyday protein-rich foods, may live nearly a year less than men with lower levels, according to a Mendelian randomization analysis built on UK Biobank data. The finding draws on metabolomic measurements from more than 118,461 participants and parental survival records from 389,166 individuals, linking a routine blood biomarker to a measurable reduction in lifespan. Sex-stratified results pointed to a sharper effect in men, one that was not fully explained by blood-pressure pathways examined in earlier genetic research.
Phenylalanine, male lifespan, and the gap in current evidence
Phenylalanine is an essential amino acid the body cannot produce on its own. It enters the bloodstream through dietary protein, including meat, dairy, eggs, and legumes, and serves as a building block for neurotransmitters and other molecules. Most people process it without trouble, but genetic variation can push circulating levels higher or lower across a population. The new analysis used those natural genetic differences as instruments to test whether higher phenylalanine concentrations cause shorter lifespans rather than simply correlating with them.
The technique, called Mendelian randomization, treats inherited gene variants like a randomized experiment. Because variants are assigned at conception, they are less likely to be tangled up with lifestyle habits or other confounders. In this case, researchers identified variants linked to higher phenylalanine and then checked whether carriers of those variants also showed shorter parental lifespans, a well-established proxy for an individual’s own survival prospects. The result for men was a reduction approaching one year of life.
Earlier Mendelian randomization work had already connected circulating amino acids to blood pressure, a known driver of cardiovascular disease and premature death. A peer-reviewed study using UK Biobank metabolite profiling documented that the Nightingale platform measures phenylalanine and tyrosine among its amino-acid panel, and explored causal links between those amino acids and blood-pressure traits. That research established one plausible biological route from phenylalanine to shorter life. But the newer lifespan analysis suggests the amino acid’s influence on survival extends beyond blood pressure alone, raising the possibility that multiple disease pathways are involved.
How UK Biobank metabolomics and longevity genetics produced the finding
Two large-scale datasets form the backbone of the analysis. The first is the Nightingale Health nuclear magnetic resonance (NMR) metabolomics resource within the UK Biobank. An atlas of biomarkers published in Nature Communications documented the pipeline’s scope: 118,461 individuals with standardized blood-sample handling, quality control, and a broad panel of biomarkers that includes amino acids. Phenylalanine and tyrosine sit within the platform’s “Other Amino Acid” set, as confirmed by an integrative metabolite analysis that mapped genetic architecture across dozens of circulating metabolites.
The second pillar is a body of genome-wide association studies focused on human longevity. One study identified 25 genetic loci associated with lifespan in 389,166 UK Biobank participants, using parental attained ages as the phenotype. A later meta-analysis scaled the approach to genomics of roughly one million parent lifespans, drawing on UK Biobank data alongside other cohorts and identifying disease pathways, including cardiovascular disease, that shape survival chances. Together, these datasets gave researchers the genetic instruments on the exposure side (phenylalanine-raising variants) and the outcome side (lifespan-linked variants) needed for a Mendelian randomization test.
When the analysis was stratified by sex, the effect in men was more pronounced. The blood-pressure instruments validated in earlier work could account for part of the association, but a residual signal persisted. That residual gap is where the hypothesis of independent, non-blood-pressure mechanisms gains traction. Phenylalanine feeds into tyrosine metabolism, catecholamine synthesis, and inflammatory signaling, any of which could contribute to organ damage or disease risk through routes that do not register on a standard blood-pressure reading.
Unanswered questions about phenylalanine and sex-specific survival
Several pieces of the puzzle are still missing. The primary UK Biobank NMR release files and longevity GWAS summary statistics do not currently include sex-stratified effect-size tables for phenylalanine on parental attained age. That means the reported male-specific finding has not yet been replicated in a fully independent, publicly available dataset with the same breakdown. Researchers working with approved UK Biobank applications can request individual-level data, but those projects and their exact covariate choices are not disclosed in the companion documentation.
There is also no direct, participant-level linkage between measured amino-acid concentrations and verified death certificates in the cited primary papers. The parental lifespan approach is an indirect phenotype: it infers a person’s own survival prospects from how long their parents lived, adjusted for factors such as birth year and sex. This strategy boosts statistical power and allows large-scale genetic analysis, but it introduces assumptions about shared environment and generational changes in healthcare that are not fully captured in the models.
Another open question is why the apparent effect is stronger in men. One possibility is that men and women differ in how they handle aromatic amino acids at the hormonal, enzymatic, or tissue level. Sex hormones can influence liver enzyme expression, vascular tone, and inflammatory cascades, all of which might modulate the downstream impact of elevated phenylalanine. Alternatively, the difference could reflect gene–environment interactions, such as sex-specific patterns of diet, smoking, or medication use that interact with genetically driven metabolite levels.
However, the current evidence base is not sufficient to distinguish among these explanations. The observational literature on phenylalanine outside of rare inborn errors of metabolism is thin, and most clinical attention has focused on patients with phenylketonuria, who have dramatically higher levels than those seen in the general population. The genetic analyses in UK Biobank involve much subtler shifts in concentration, and it remains unclear how those modest differences translate into specific disease endpoints like myocardial infarction, stroke, or neurodegeneration.
Methodological caveats also apply. Mendelian randomization relies on the assumption that the genetic variants used as instruments affect lifespan only through their impact on phenylalanine, not through other biological pathways. If a variant influences both phenylalanine and, for example, lipid metabolism or immune function, the resulting estimates could be biased. Sensitivity analyses can probe for such “pleiotropy,” but they cannot rule it out entirely, especially when the number of available instruments is limited.
What this means – and does not mean – for diet and prevention
For now, the findings do not justify specific dietary recommendations about phenylalanine for the general population. The genetic instruments capture lifelong tendencies toward higher or lower levels, not the short-term effects of changing protein intake. Foods that contain phenylalanine also provide many other nutrients, and no trial evidence currently shows that lowering phenylalanine within the normal range in otherwise healthy adults extends life.
Instead, the work highlights phenylalanine as a potential biomarker and mechanistic clue. If replicated and refined, genetically informed estimates of its impact on survival could motivate more detailed studies of how aromatic amino acids interact with cardiovascular, renal, and neuroendocrine systems. Such research might eventually identify subgroups – defined by genotype, comorbidities, or co-exposures – for whom managing phenylalanine or its metabolic products could be clinically relevant.
In the meantime, the core public-health message remains anchored in established risk factors. Blood pressure, lipid levels, smoking, obesity, and physical inactivity all have far stronger and more directly demonstrated effects on lifespan than any single amino acid. The emerging genetic evidence on phenylalanine adds nuance to the picture of cardiometabolic risk, but it does not overturn decades of epidemiology or clinical trial data that underpin current prevention guidelines.
As larger biobanks, richer metabolomic panels, and more detailed mortality records become available, researchers will be able to revisit the phenylalanine–lifespan link with greater precision. Sex-specific analyses, integration with disease registries, and triangulation with other causal-inference methods should clarify whether the approximate one-year reduction in male lifespan is robust, which conditions mediate it, and whether any practical interventions can safely modify the risk. Until then, phenylalanine’s role in human ageing remains a compelling, but still provisional, piece of the broader longevity genetics puzzle.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
